Patients should contact their healthcare provider promptly if they experience: Severe, persistent abdominal pain that worsens or differs from typical bloating Inability to pass gas or have bowel movements (possible obstruction) Persistent vomiting that prevents adequate hydration or medication adherence Unintentional weight loss beyond expected therapeutic effects Blood in stool or black, tarry stools Fever accompanying gastrointestinal symptoms Right upper quadrant pain or yellowing of skin/eyes (possible gallbladder disease) Severe constipation with abdominal distension (possible ileus/obstruction) Signs of dehydration (excessive thirst, dark urine, dizziness) These symptoms may indicate complications such as pancreatitis, gallbladder disease, bowel obstruction, or acute kidney injuryall noted in FDA prescribing information as potential risks
This pattern is broadly consistent with a model in which semaglutide alters reward prediction errors or the valuation of behavioral outcomes, thereby reducing the anticipatory salience or hedonic impact of voluntary movement
Luo Y, Li Z, Ge P, Guo H, Li L, Zhang G, Xu C, Chen H
S dng cho bnh nhn i thao ng, suy gim min dch, mch mu no, nguy c tai bin th bnh nhn s dng e gluta theo ch nh ca bc s
It looks like nothing was found at this location
